What Paradromics does

Paradromics is a clinical-stage neurotechnology company developing high-data-rate, fully implantable brain-computer interfaces (BCIs). Founded in 2015 and headquartered in Austin, Texas, with a secondary Machine Learning and Data Science office in Oakland, California, the company is building a modular intracortical BCI platform designed to read and write neural activity at single-neuron resolution. Its current clinical product, the Connexus® BCI, uses 421 microelectrodes—each smaller than a human hair and extending 1.5mm into the cortex—to capture signals from individual neurons and transmit them wirelessly via a near-infrared optical link to an external receiver. Neural signals are decoded by machine-learning algorithms and language models into synthesized speech, text, and computer commands at demonstrated information transfer rates exceeding 200 bits per second, which the company states is approximately 20x faster than existing BCIs. A pipeline product, Tempo™ BCI, scales the architecture to roughly 1,000 microelectrodes per cortical module and targets ambulatory users with broader applications including speech restoration, computer control, upper-limb prosthetic control, and brain-state monitoring.

The company is pre-revenue and operates under FDA investigational-use restrictions. Its go-to-market runs through the FDA-authorized Connect-One Early Feasibility Study, enrolling adults aged 22-75 with ALS, spinal cord injury, or brainstem stroke at three U.S. clinical sites: University of Michigan Health (Ann Arbor), UC Davis Health (Sacramento), and Massachusetts General Hospital (Boston). Participants are followed for up to six years. Patient recruitment is supplemented by a BCI Community and patient registry accessible through the company's website. Forward revenue mechanics are expected to combine hardware sales of the Connexus system with potential platform licensing across adjacent neurological applications, though no commercial pricing is publicly disclosed.

Paradromics has accumulated material regulatory and partnership momentum: two FDA Breakthrough Device Designations (speech decoding in March 2023; digital device control in April 2024), FDA Total Product Life Cycle Advisory Program (TAP) acceptance in July 2024, and FDA Investigational Device Exemption (IDE) approval in November 2025, followed by the first long-term human Connexus implantation in June 2026. Leadership is led by founder and CEO Matt Angle, PhD, with BCI veteran Vikash Gilja, PhD as CSO, neurosurgeon Stephen Ryu, MD as CMO, and Kurtis Nishimura, PhD as CTO. The APEX Partnership Program (March 2026) extends research collaboration with Stanford University, Massachusetts General Hospital, the University of Pittsburgh, the University of Michigan, and UC Davis Health, while a February 2025 strategic partnership with NEOM Investment Fund supports a BCI Center of Excellence in Saudi Arabia. Prime Movers Lab has led multiple funding rounds, including the July 2021 $20M seed and a $50.1M Series 2 in May 2023, with cumulative disclosed funding exceeding $51M.

Name

Paradromics

Legal name

Paradromics, Inc.

Website

https://paradromics.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

51–100 employees

Short description

Paradromics is a clinical-stage neurotechnology company developing fully implantable, high-data-rate brain-computer interfaces to restore speech, communication, and computer control for patients with severe motor impairment from ALS, spinal cord injury, and stroke.

Ownership category

akta.pro rank

Product category

Implantable brain-computer interfaces / Neurotechnology medical devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)

akta.pro secondary industries

Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE), Assistive & Accessibility Input Devices (Switches, Adaptive Controllers, Braille Keyboards) (HDACAFAL)

Keywords

• Brain-computer interfaces
• Implantable neurotechnology
• Speech restoration devices
• Intracortical neural recording
• Neural decoding platforms

Headquarters

HQ city

Austin

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Commercialization: Paradromics is a clinical-stage neurotechnology company developing the Connexus BCI system for restoring speech and communication in patients with severe motor impairment. The company plans to commercialize its BCI platform following successful clinical trials and FDA approval. Initial indications target ALS, spinal cord injury, and stroke patients, with future expansion to additional neurological conditions.
2. Future Platform Licensing: The company's modular BCI architecture supports application expansion, with potential for connecting multiple high-performing modules to different brain regions. This platform approach may enable licensing opportunities for various neurological applications including prosthetics control, sensory restoration, and cognitive interfaces.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

Paradromics is developing and clinically validating a high-data-rate, fully implantable, wireless brain-computer interface (Connexus® BCI) that uses 421 microelectrodes to record from individual neurons and translate neural signals into synthesized speech, on-screen text, and computer control commands for patients who have lost the ability to communicate due to ALS, spinal cord injury, or brainstem stroke. The platform is being evaluated in the FDA-approved Connect-One Early Feasibility Study, with a next-generation pipeline product (Tempo™ BCI) targeting ambulatory users and expanded applications including prosthetics control, sensory restoration, and cognitive interfaces.

Product overview

Paradromics is building a modular brain-computer interface platform designed for high-data-rate neural recording and decoding. The current clinical product is Connexus® BCI, an FDA-approved investigational device for speech restoration and computer control. The pipeline product is Tempo™ BCI, targeting active-life users with expanded applications. The platform's modular architecture supports application expansion, with current capabilities focused on communication and computer control, and future applications including precision prosthetics, neuromodulation, sensory restoration, and cognitive interfaces.

Differentiator

Problem solved

Functional benefit

Brands

• Connexus® BCI: The first high-data-rate brain-computer interface designed for long-term medical use, currently in FDA-approved clinical trials for speech restoration.
• Tempo™ BCI

Products and services

• Connexus® BCI The first high-data-rate, fully implantable, wireless brain-computer interface designed for long-term medical use. Uses 421 microelectrodes to capture signals from individual neurons and translates them into synthesized speech, text, and computer control commands at over 200 bits per second. Currently in FDA-approved clinical investigation for patients with ALS, spinal cord injury, and brainstem stroke.
• Tempo™ BCI Pipeline next-generation high-data-rate BCI for active-life users, featuring over 2x the electrode channels (~1,000 microelectrodes per cortical module) versus Connexus in the same form factor. Designed to be rechargeable, wireless, and ambulatory, targeting expanded applications including speech restoration, computer control, upper-limb prosthetic control, and continuous brain-state monitoring for mental health. Currently in pre-clinical trial phase.

Quantifiable outcome

• 200+ bits per second information transfer rate, 20x faster than existing BCIs
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

Partnerships

Six partnerships are on record, tiered core.

• University of Michigan HealthcoreImplementation/ SI/ Consulting Partner · 17 June 2026Paradromics and University of Michigan Health completed the first Connexus BCI implantation in the FDA-approved Connect-One Clinical Study. The procedure was performed by Dr. Matthew Willsey and his multidisciplinary team. University of Michigan Health serves as a primary clinical trial site.
• Stanford University (Jaimie Henderson, MD and Frank Willett, PhD)coreStrategic or Co-development Partner · 17 March 2026APEX Partnership Program collaboration with Stanford University researchers working on expanding BCI clinical scope via multi-regional targeting protocols. Dr. Henderson is a leader in image-guided functional neurosurgery, and Dr. Willett is a prominent scientist whose work in neural decoding has set world records for BCI-enabled communication.
• Massachusetts General Hospital (Dan Rubin, MD, PhD)coreStrategic or Co-development Partner · 17 March 2026APEX Partnership Program collaboration with Dr. Dan Rubin, critical care neurologist and leading BCI researcher. Dr. Rubin is an expert in recovery from acute brain injury, director of the nation's first dedicated BCI clinic, and leads research on clinical translation of BCI technology. He serves as site investigator for Connect-One Clinical Study.
• University of Pittsburgh (Jennifer Collinger, PhD and Robert Gaunt, PhD)coreStrategic or Co-development Partner · 17 March 2026APEX Partnership Program collaboration exploring motor and sensory function restoration for individuals with upper limb paralysis. Their decades of pioneering work in physical medicine and spinal cord injury sets the stage for bidirectional interfaces that restore both movement and sense of touch.
• University of Michigan Health (Matthew Willsey, MD, PhD)coreStrategic or Co-development Partner · 17 March 2026APEX Partnership Program collaboration with Dr. Matthew Willsey, who established one of the nation's first BCI clinics to research speech and motor assistive devices. Dr. Willsey performed the first human Connexus BCI implantation surgery in June 2026 at University of Michigan Health.
• UC Davis Health (David Brandman, MD, PhD)coreStrategic or Co-development Partner · 17 March 2026APEX Partnership Program collaboration with Dr. David Brandman, Associate Professor of Neurosurgery at UC Davis. Dr. Brandman serves as Lead Principal Investigator of the Connect-One Clinical Study and investigates speech restoration for people who have lost muscle control needed to talk.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Kernel: Kernel develops non-invasive neuroimaging and brain-interface technology (Kernel Flow, Kernel Echo). While its modality is non-invasive rather than implantable, it competes in the broader BCI category with cognitive and neural monitoring applications.
• Neuralink: Neuralink is the highest-profile direct competitor in implantable intracortical BCIs, developing high-channel-count brain implants for motor control and communication. It competes head-to-head with Paradromics in the speech-restoration and motor-control indications and has achieved significantly more public attention and capital.
• Synchron: Synchron develops a less-invasive endovascular (stentrode) BCI for patients with severe motor impairment. While Paradromics is intracortical, both target the same primary patient populations (ALS, paralysis) with speech restoration and computer control as core use cases.
• Blackrock Neurotech: Blackrock Neurotech pioneered Utah-array intracortical BCI technology and has decades of clinical research deployments. It competes with Paradromics on high-channel neural recording for motor and communication applications and is a long-standing player in the academic BCI space.
• Precision Neuroscience: Precision Neuroscience is developing a high-resolution cortical surface BCI (Layer 7) targeting motor and speech restoration. It is a direct competitor in the implantable BCI category focused on similar patient populations and indications.
• BrainCo: BrainCo develops both non-invasive wearables and implantable BCIs for education, health, and prosthetics applications. Its prosthetics work (BrainRobotics) overlaps with Paradromics' planned upper-limb prosthetic control use case.

Emerging players

• Motif Neurotech: Motif Neurotech is developing minimally invasive brain stimulation devices for mental health indications. While its modality (stimulation) and use case (mental health) differ from Paradromics' recording-focused platform, it operates in the broader implantable neurotechnology category.
• Inbrain Neuroelectronics: Inbrain Neuroelectronics develops graphene-based cortical interfaces for both recording and stimulation. It targets neurological and mental health indications and competes in the implantable BCI space, though with a different electrode material and application focus.

Broad incumbents

• Medtronic: Medtronic is a global leader in implantable neurotechnology, including deep brain stimulation (DBS), spinal cord stimulation, and other neuromodulation devices. It is a broad incumbent in the implantable neuro device space where Paradromics ultimately intends to compete.
• Abbott: Abbott (via St. Jude Medical) is a major incumbent in neuromodulation with FDA-approved DBS and spinal cord stimulation systems. It represents an established competitor with deep clinical relationships and commercial infrastructure that Paradromics will eventually need to match.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/paradromics
• LinkedInlinkedin.com/company/paradromics-inc

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds13 records

Investors29 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Paradromics